01569: Evaluation of a Novel Drug to Treat Canine Cutaneous Lymphoma

Grant Status: Closed

Grant Amount: $37,844
Douglas H Thamm, VMD; Colorado State University
March 1, 2012 - December 31, 2013

Sponsor(s): American Shih Tzu Club, Inc., Flat-Coated Retriever Foundation, Giant Schnauzer Club of America, Golden Retriever Foundation, Gordon Setter Club of America, National Beagle Club, National Foxhunters Association, Samoyed Club of America Education & Research Foundation

Breed(s): -All Dogs
Research Program Area: Oncology - Lymphoma
Donate to Support this Research Program Area

Project Summary

Canine lymphoma is one of the most common cancers encountered in veterinary oncology. While most canine multicentric lymphoma patients initially respond to currently available chemotherapy protocols, response rates are considerably lower in patients with cutaneous T cell lymphoma (CTCL), and generally brief in duration. We previously demonstrated the effectiveness of the novel cancer drug GS-9219 (currently referred to as VDC-1101) in dogs with multicentric lymphoma, in which 100% of chemotherapy-na�ve and 60% of chemotherapy-relapsed patients experienced responses. One of the observed toxicities in VDC-1101 treated dogs was a skin change characterized by hair loss, redness and itching, implying significant delivery of VDC-1101 to the skin. Given the lack of durable effective therapy for canine CTCL, and the demonstrated anti-lymphoma activity and apparent skin accumulation of VDC-1101, evaluated the effectiveness of VDC-1101 in canine CTCL through the completion of a phase-II clinical trial. 11 dogs were evaluable; 45% of patients experienced objective improvement (1 complete response, 4 partial responses and 2 dogs experienced stable disease for an overall disease control rate of 64%). This includes one dog that experienced a complete response that has persisted for more than 1 year. Adverse effects were generally mild and self-limiting. In conclusion, VDC-1101 appears to have activity against canine CTCL, with a favorable adverse effect profile. One patient has experienced a complete and unusually durable response.


Morges, M. A., Burton, J. H., Saba, C. F., Vail, D. M., Burgess, K. E., & Thamm, D. H. (2014). Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell Lymphoma. Journal of Veterinary Internal Medicine, 28(5), 1569–1574. https://doi.org/10.1111/jvim.12429

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Connect With Us:
Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813

   2020 GuideStar logo

© 2020 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software